12-Jan-2018 By Dan Stanton
Venture capital company Dynamk Capital has invested in FloDesign Sonics citing its acoustic wave separation technology’s application in the growing CAR T cell sector.
12-Dec-2017 By Dan Stanton
Abzena has negotiated the lease on a 50,000 square foot site in San Diego as part of a $17m remodelling of its bioproduction and conjugation facilities.
06-Oct-2016 By Dan Stanton
The strong adoption of single-use technology is enabling industry to transition towards continuous bioprocessing systems, says Pall Corporation.
05-May-2016 By Melissa Fassbender
Pall Life Sciences recently announced its Cadence Acoustic Separator (CAS) for clarifying biologic products in a single-use format.
19-Sep-2014 By Dan Stanton
Genzyme has filed a patent application for a technology platform that will bridge the gap between upstream and downstream processing in continuous biomanufacturing.
03-Sep-2014 By Gareth Macdonald
Biopharmas scaling-up production should use fluid dynamics to make better predictions about bioreactor performance according to one expert, who says engineers can use it to test multiple configurations more rapidly.
27-Jun-2014 By Gareth Macdonald
Fujifilm Diosynth Biotechnologies has expanded process development capacity at its site in the UK with a new $5.6m investment and a TAP bioreactor.
20-Dec-2013 By Gareth Macdonald
Sartorius has confirmed it will make the Ambr microreactor technology it acquired with Tap Biosystems compatible with its own downstream processing systems.
22-Nov-2013 By Gareth Macdonald
GE Healthcare has launched new single-use, bioreactor for seed train and process development operations and mAb production.
Batavia gains bioprocessing assets in Xendo collaboration
29-Aug-2011 By Nick Taylor
Batavia Bioservices has gained access to simulated moving bed (SMB) technology by collaborating with Xendo.
SSB launches small-scale disposable reactor
Sartorius Stedim Biotech (SSB) has launched a new small-scale bioreactor citing growing biopharmaceutical company demand for scale-up technologies as the key driver for its development.
Pall and New Brunswick partner on disposable bioreactors
15-Jun-2010 By Gareth Macdonald
Pall and New Brunswick have teamed up to develop and supply new disposable bioreactor technologies, targeting growing demand for products that improve quality and reduce cost of biomanufacturing.
Xcellerex adding FlexFactory to Massachusetts HQ
10-Jun-2010 By Nick Taylor
Xcellerex is building a second cGMP FlexFactory biomanufacturing facility to support clients transitioning to their own plants and provide contract manufacturing services.
Mircofluidics launches continuous nanocrystallisation tech
22-Apr-2010 By Staff Reporter
Microfluidics chose Interphex 2010 in New York, US to unveil a new processing technology that it claims can help manufacturers save time and money by switching from batch to continuous particle production.
SAFC launches Ex-cell Antifoam for biomanufacturing
26-Nov-2009 By Staff Reporter
SAFC Biosciences hopes Ex-Cell Antifoam, its new foam control product for cell culture bioreactors, will work the biomanufacturing sector into a lather.
26-Mar-2009 By Gareth Macdonald
Flexibility is going to be a key driver for the pharmaceutical market in the next few years, according to Millipore's VP of downstream processing Paul Chapman.
Novasep teams up with Rohm and Haas
Novasep and Rohm and Haas have forged a strategic alliance to
provide separation media, processes and systems for manufacturers
of biologic drugs.
Novasep unveils new divisional structure
Groupe Novasep has provided an update on the structural changes at
the company in the wake of its merger with Dynamic Synthesis in
Process speeds up plasmid purification
Boehringer Ingelheim and Slovenian company BIA Separations have
collaborated on a new separation and purification system that
should improve the production of plasmid DNA.
Contract biopharma plant opens in Finland
In an unusual move, Finnish science park Medipolis has set up a new
Good Manufacturing Practice (GMP) pilot plant to take advantage of
the growing demand for biopharmaceutical production capacity.